An Open Label, Escalation Study to Assess Intra-Subject Dose Response to VA106483 in Elderly Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 25 May 2018
At a glance
- Drugs Fedovapagon (Primary)
- Indications Nocturia
- Focus Pharmacokinetics
- 09 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2009 New trial record